Big

  • US FDA approves KOMBIGLYZE XR

    The US FDA approved Bristol-Myers Squibb ( BMS ) and Astrazeneca ’s KOMBIGLYZE XR for the treatment of type 2 diabetes in adults. KOMBIGLYZE XR is the first and only once-a-day metformin extended-release (XR) plus dipeptidyl peptidase-4 (DPP-4)…

    Big | 05 January 2011

  • Bigger market share for RA biologic treatments

    Use of biologic disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis is set to increase dramatically over the next five years, says independent market analyst Datamonitor . Despite their considerable cost, rheum…

    Big | 15 October 2010

  • Big Pharma Struggles to Benefit from Increased CVD Drug Usage

    Pharmaceutical (Pharma) companies will struggle to profit from the Cardiovascular Disease (CVD) market over the next decade despite growing drug usage, according to Datamonitor. It is predicted that the CVD pharma market will grow from US$99 billion …

    Big | 17 March 2010

  • Biopharmaceuticals: Shifting Landscapes

    The industry is undergoing changes as Big Pharma buys out smaller biotech and pharmaceutical companies.

    Big | 01 March 2010

  • Vaccines: Big Players Push into Asia

    Vaccines have become an important revenue driver for the pharmaceutical industry. Facing the patent cliff of their existing portfolio of drugs, and encouraged by the emergence of blockbuster vaccines, almost all major pharmaceutical companies have e…

    Big | 01 January 2010

  • Big Pharma Seeks to Insulate Itself from the

    As the pharmaceutical industry moves closer towards the ‘patent cliff’, Big Pharma is implementing strategies to lessen the impact of the loss of patent protection on some of the industry’s biggest sellers on their collective bottom lines. …

    Big | 01 November 2009

  • Big pharma looks for strategies to fight the decline

    In an effort to survive declining profits and drug failures, the pharmaceutical industry is turning to layoffs and outsourcing. While many consider these trends a knee-jerk reaction, people who pull the strings in these companies have a different…

    Big | 19 September 2008

  • Study: Aggressive TB Control Can Yield Big Economic Gains

    A new World Bank research report finds that 22 countries with the world’s highest numbers of TB cases could earn significantly more than they spend on TB diagnosis and treatment if they signed onto a global plan to sharply reduce the numbers of TB-…

    Big | 23 January 2008

  • Small World, Big Dreams

    The US Food and Drug Administration (FDA) appears to be taking a cautious, deliberative approach as it approaches the myriad of scientific and regulatory issues involving nanobiotechnology and nanomedicine. After nearly a year of study, the FDA’s N…

    Big | 01 November 2007

  • Big Pharma, Big Money

    Facing a myriad of challenges including anemic pipelines, regulatory uncertainty, investment doldrums, and diminishing public perception, the pharmaceutical industry worldwide is at a crossroads. Three reports released this summer assess the future o…

    Big | 01 September 2007

Page 1 Next > Last >>